top of page

Janssen’s Stelara approved in Europe for pediatric plaque psoriasis

The Janssen Pharmaceutical Company of Johnson and Johnson announced that European Commission approved the use of Stelara (Ustekinumab) in pediatric patients with plaque psoriasis. The drug has been earlier approved for adolescents and adults with plaque psoriasis.

“This latest EC approval is a significant milestone for young children struggling to cope with the symptoms of psoriasis,” said Lloyd Miller, Vice President, Immunodermatology Disease Area Leader, Janssen Research & Development, LLC.

The approval of the drug was based on Phase 3 CADMUS Jr study building on prior Phase 3 CADMUS study. The primary endpoint was percentage of patients who achieved physician’s global assessment (PGA) score of Cleared (0) or Minimal (1) at week 12. Psoriasis area and severity index of ≥75% (PASI 75), ≥90% (PASI 90), and change from baseline in Children’s Dermatology Life Quality Index (CDLQI) at week 12 were considered as secondary endpoints.

Study results at week 12 were:

· 77.3% achieved PGA 0/1

· 84.1% achieved PASI 75

· 63.6% achieved PASI 90

About Psoriasis

Psoriasis is an autoimmune disorder that manifests in the skin. Plaque psoriasis is most common psoriasis, manifested by inflamed and red skin. The diseases have severe impact on quality of life of patients.

About Stelara

Stelara is indicated for psoriasis, pediatric plaque psoriasis, psoriatic arthritis, Crohn's disease (CD) and ulcerative colitis (UC). Janssen holds exclusive worldwide rights on Stelara.


Recent Posts

See All

Australia Healthcare News | Media | Updates

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease For women facing advanced or recurring endometrial cancer, a medication called Jemperli (dosta


bottom of page